DE69926254D1 - Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden - Google Patents

Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden

Info

Publication number
DE69926254D1
DE69926254D1 DE69926254T DE69926254T DE69926254D1 DE 69926254 D1 DE69926254 D1 DE 69926254D1 DE 69926254 T DE69926254 T DE 69926254T DE 69926254 T DE69926254 T DE 69926254T DE 69926254 D1 DE69926254 D1 DE 69926254D1
Authority
DE
Germany
Prior art keywords
beta
inhibitors
radioligands
preparation
amyloid peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69926254T
Other languages
English (en)
Inventor
C Zaczek
E Olson
A Seiffert
Andrew Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of DE69926254D1 publication Critical patent/DE69926254D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DE69926254T 1998-11-12 1999-11-12 Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden Expired - Lifetime DE69926254D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10814798P 1998-11-12 1998-11-12
US13128499P 1999-04-27 1999-04-27
PCT/US1999/026715 WO2000028331A1 (en) 1998-11-12 1999-11-12 Use of radioligands to screen inhibitors of amyloid-beta peptide production

Publications (1)

Publication Number Publication Date
DE69926254D1 true DE69926254D1 (de) 2005-08-25

Family

ID=26805566

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69926254T Expired - Lifetime DE69926254D1 (de) 1998-11-12 1999-11-12 Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden

Country Status (8)

Country Link
US (1) US6331408B1 (de)
EP (1) EP1129355B1 (de)
AT (1) ATE300052T1 (de)
AU (1) AU1618000A (de)
CA (1) CA2346099A1 (de)
DE (1) DE69926254D1 (de)
NO (1) NO20011891L (de)
WO (1) WO2000028331A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331408B1 (en) * 1998-11-12 2001-12-18 Robert Zaczek Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1313426A4 (de) 1998-12-24 2003-05-28 Bristol Myers Squibb Pharma Co Succinoylaminobenzodiazepine als inhibitoren der a-beta proteinproduktion
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
EP1261610A2 (de) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino-carbocyclen und -heterocyclen als hemmer der a-beta-proteinbildung
BR0110051A (pt) 2000-04-03 2004-12-07 Bristol Myers Squibb Pharma Co Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
WO2001092235A1 (en) 2000-06-01 2001-12-06 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
ES2662177T3 (es) * 2001-04-20 2018-04-05 University Of Georgia Research Foundation, Inc. Inactivadores de sitio activo
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
EP1841455A1 (de) * 2005-01-24 2007-10-10 Amgen Inc. Humanisierter anti-amyloid-antikörper
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
EP2897954B1 (de) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoralkyl-1,4-benzodiazepinon-verbindungen
WO2014047390A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
EP2897946B1 (de) 2012-09-21 2016-11-16 Bristol-Myers Squibb Company N-substituierte bis(fluoralkyl)-1,4-benzodiazepinonverbindungen
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
EP2897947B1 (de) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1, 4-benzodiazepinonverbindungen
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
US9133126B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzoazepinone compounds
WO2014165718A1 (en) 2013-04-04 2014-10-09 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5252463A (en) * 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5538845A (en) * 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5594006A (en) * 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
EP0763537A3 (de) * 1993-05-14 1997-10-22 Genentech Inc Nichtpeptide Farnesyltransferas Inhibitoren
NZ264143A (en) * 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US5734054A (en) * 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
US6331408B1 (en) * 1998-11-12 2001-12-18 Robert Zaczek Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production

Also Published As

Publication number Publication date
NO20011891D0 (no) 2001-04-17
AU1618000A (en) 2000-05-29
EP1129355B1 (de) 2005-07-20
EP1129355A1 (de) 2001-09-05
NO20011891L (no) 2001-07-02
CA2346099A1 (en) 2000-05-18
ATE300052T1 (de) 2005-08-15
US6331408B1 (en) 2001-12-18
WO2000028331A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
DE69926254D1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
MY131442A (en) Excitatory amino acid receptor antagonists
ATE491721T1 (de) Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten
DE69432629D1 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
EA200401365A1 (ru) Способы лечения илеуса
NO20006645D0 (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
WO2001087354A3 (en) Use of small molecule radioligands for diagnostic imaging
DE69025472D1 (de) Dopamin-agonisten
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
RO116898B1 (ro) Derivaţi de dioxizi de benzotiazină, procedeu pentru prepararea acestora, intermediari, compoziţie farmaceutică şi metodă pentru inhibarea nivelurilor crescute de endotelină
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DK1373502T3 (da) Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
NO20051664L (no) Behandling av demens og Parkinsons sykdom
DE69808475T2 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
NO975413D0 (no) Koboltmetallagglomerater, samt fremgangsmåte for fremstilling og anvendelse derav
NO975961L (no) Fremgangsmåte for fremstilling av 1-(3-trialkylsilylfenyl)-2,2,2-trifluorometyl-ethanonderivater
WO1999006838A3 (en) Novel method of detecting amyloid-like fibrils or protein aggregates
WO2003045325A3 (en) Dopaminergic stimulatory factor
ATE420637T1 (de) Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems

Legal Events

Date Code Title Description
8332 No legal effect for de